About This Calculator

The Cyltezo (adalimumab-adbm) Dosing Calculator is an educational tool designed to assist healthcare professionals in determining the appropriate induction and maintenance dosing schedules based on the U.S. Prescribing Information. It considers patient-specific factors such as indication, age, and weight to provide regimen recommendations for various inflammatory conditions.

Outputs

After entering the required patient data, the calculator provides a clear, concise dosing summary. The output includes:

  • Recommended Dose: The specific milligram (mg) dosage for induction and/or maintenance phases.
  • Dosing Frequency: The administration schedule, such as "every other week" or "every week."
  • Patient-Specific Tags: Key information like patient type (Adult/Pediatric) and weight in kilograms.
  • Clinical Notes: Important context from the prescribing information, such as considerations for monotherapy or the duration of induction therapy.

How to Use

To use the calculator, follow these steps:

  1. Select Indication: Choose the patient's approved medical condition from the dropdown menu (e.g., Rheumatoid Arthritis, Crohn’s Disease).
  2. Enter Patient Age: Input the patient's age in years. This helps determine if adult or pediatric dosing guidelines apply.
  3. Enter Patient Weight: Provide the patient's weight and select the appropriate units (kg or lbs). The tool will automatically convert as needed.
  4. Specify Phase/Therapy (if applicable): For certain indications, you may need to specify the dosing phase (Induction/Maintenance) or if Cyltezo is used with methotrexate.
  5. Calculate: Click the "Calculate Dose" button to generate the dosing regimen.

Dosing Overview

Dosing for Cyltezo (adalimumab-adbm) is specific to the indication and patient population. Below is a general summary:

  • Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis (Adults): The standard dose is 40 mg administered every other week. For RA patients not on concomitant methotrexate, the frequency may be increased to 40 mg every week.
  • Crohn’s Disease & Ulcerative Colitis (Adults & Pediatrics ≥40 kg): Dosing begins with a 160 mg induction dose on Day 1, followed by 80 mg on Day 15. The maintenance dose is 40 mg every other week, starting on Day 29. Pediatric patients under 40 kg receive lower induction and maintenance doses.
  • Plaque Psoriasis & Uveitis (Adults): Treatment starts with an initial 80 mg dose, followed by a maintenance schedule of 40 mg every other week beginning one week after the initial dose.
  • Juvenile Idiopathic Arthritis (Pediatrics ≥2 years): Dosing is weight-based, ranging from 10 mg to 40 mg every other week.

Switching Therapy

The decision to switch a patient from another biologic agent to Cyltezo should be made by a qualified healthcare provider. Considerations include the previous medication's half-life, the patient's clinical status, and disease activity. There is no one-size-fits-all protocol, and the transition must be managed on an individual basis, following the Cyltezo prescribing information for the initial dosing schedule.

Missed Dose

If a patient misses a dose of Cyltezo, they should be instructed to administer the injection as soon as they remember. They should then take their next dose at the regularly scheduled time. Patients should not take two doses at once to make up for a missed one. Advise patients to consult their healthcare provider for specific guidance.

Safety Alerts

Cyltezo, like other TNF-alpha inhibitors, has important safety warnings. The U.S. Prescribing Information includes a Boxed Warning regarding the increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, and invasive fungal infections. There is also an increased risk of lymphoma and other malignancies. Patients should be screened for latent TB before initiating treatment. This calculator does not replace a thorough review of the full safety information and prescribing label.

Frequently Asked Questions

  • Why is patient age required for the calculation?
    Age is critical to differentiate between adult and pediatric dosing guidelines, as dosages and approved indications vary significantly between these groups.
  • Which indications include an induction dosing phase?
    Indications such as Crohn’s Disease, Ulcerative Colitis, Plaque Psoriasis, Hidradenitis Suppurativa, and Uveitis require an initial higher or more frequent induction dose before starting the maintenance schedule.
  • Why does the "Concomitant Therapy" option appear only for Rheumatoid Arthritis?
    The prescribing information for RA specifically notes a potential dose frequency adjustment (to weekly) for patients on monotherapy, making this distinction clinically relevant.
  • What happens if I enter a weight below the approved range for an indication?
    The calculator will display an error message, as dosing information is not available for patients outside the weight parameters specified in the clinical trials and prescribing information (e.g., <10 kg for JIA).
  • How does the calculator handle weight unit conversions?
    When you enter a weight in either kg or lbs, the tool automatically displays the equivalent value in the other unit below the input field, ensuring accuracy for weight-based calculations.
  • Is the dosing for Psoriatic Arthritis (PsA) and Ankylosing Spondylitis (AS) the same in this tool?
    Yes, for adults, the recommended dose for both PsA and AS is 40 mg every other week, and the calculator reflects this.
  • Does the calculator account for dose escalation?
    The tool provides the standard, approved dosing regimens. However, it includes clinical notes where the prescribing information mentions the possibility of dose escalation (e.g., increasing to weekly for RA monotherapy or Crohn's Disease).
  • What Cyltezo formulations are mentioned by the calculator?
    The calculator notes the availability of a 40 mg/0.8 mL Pen and a 40 mg/0.8 mL Prefilled Syringe, which are common formulations used for delivering the recommended doses.
  • What should I do if the calculator's output seems unexpected?
    Always verify the calculated dose against the full, most current U.S. Prescribing Information for Cyltezo. This tool is for educational support and is not a substitute for clinical judgment.

References

PRO
Ad-Free Access
$3.99 / month
  • ✓ No Interruptions
  • ✓ Faster Page Loads
  • ✓ Support Content Creators
Subscribe Now